AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-12 (cancelled).

13. (New) A compound of formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing:



(I)

wherein:

- R_1 and R_2, each independently represent a phenyl, a thienyl, or a pyridyl group, which groups are optionally substituted with 1, 2, or 3 substituents Y, wherein said Y substituents, which may be the same or different, are each independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups, or

- R_1 or R_2, or both R_1 and R_2, represent naphthyl;

- X represents a subgroup chosen from (i) and (ii),



(i) (ii)

wherein:

- R_3 is chosen from a hydrogen atom and a branched or linear C_{1-3} alkyl group;

- R_4 is chosen from:

- a branched or linear C_{1-8}-alkyl or C_{3-8}-cycloalkyl-C_{1-2}-alkyl, branched or linear C_{1-8} alkoxy, C_{3-8} cycloalkyl, C_{5-10} bicycloalkyl, or C_{6-10} tricycloalkyl group, which groups optionally contain one or more heteroatoms chosen from O, N, and S, and which groups are optionally substituted with a hydroxy group, 1-3 methyl groups, an ethyl group, or 1-3 fluoro atoms; or

- a phenoxy, benzyl, phenethyl or phenylpropyl group, which groups are each optionally substituted on their phenyl ring with 1-3 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

- a pyridyl or thienyl group; and

- a group NR_5R_6, wherein:

- R_5 and R_6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains one or two

heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a hydroxy or a trifluoromethyl group or a fluoro atom; or

- R_3 and R_4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, an amino, a hydroxy or a trifluoromethyl group, or a fluoro atom;

- R_7 represents a benzyl, phenyl, thienyl or pyridyl group, wherein the aromatic ring of said group is optionally substituted with 1, 2, 3 or 4 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3} alkyl, a branched or linear C_{1-3} alkoxy, a phenyl, a hydroxy, a chloro, a bromo, a fluoro, an iodo, a trifluoromethyl, a trifluoromethylthio, a trifluoromethoxy, a carboxyl, a trifluoromethylsulfonyl, a cyano, a carbamoyl, a sulfamoyl, and an acetyl group; or

- R_7 represents a branched or linear C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-10} cycloalkyl, C_{5-10} bicycloalkyl, C_{6-10} tricycloalkyl, or a branched or linear C_{5-8} cycloalkenyl; a naphthyl group, an amino group, a C_{1-8} dialkylamino group, a C_{1-8} monoalkylamino group, or a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains 1 or 2 nitrogen atoms and optionally contains a heteroatom chosen from O and S, and is optionally substituted with a branched or linear C_{1-3} alkyl, phenyl, hydroxy or trifluoromethyl group or a fluoro atom;

- R_8 represents a hydrogen atom or a methyl group; and

- R_9 represents a hydrogen atom or a methyl, ethyl, or methoxy group.

14. (New) The compound as claimed in claim 13, having the formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing:



(I)

wherein:

- R_1 and R_2 each independently represent a phenyl group that is optionally substituted with 1, 2, or 3 Y substituents, wherein each of said Y substituents may be the same or different, and is independently chosen from branched or linear C_{1-3}-alkyl, branched or linear alkoxy C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

R_1 or R_2, or both R_1 and R_2 independently represent a naphthyl, a thienyl, or a pyridyl group,

- X represents a subgroup chosen from (i) and (ii):



(i) (ii)

wherein:

- R_3 represents a hydrogen atom;

- R_4 is chosen from:

- a branched or linear C_{1-8} alkyl, or a branched or linear C_{1-8} alkoxy or C_{3-8} cycloalkyl group, which groups are optionally substituted with a hydroxy group, 1-3 methyl groups, an ethyl group, or 1-3 fluoro atoms; or

- R_4 represents a phenoxy, pyridyl, or thienyl group; or

- R_4 represents a group NR_5R_6, wherein:

- R_5 and R_6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains one or two heteroatoms chosen from O, N, and S; or

- R_3 and R_4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a methyl, hydroxy, or trifluoromethyl group, or a fluoro atom;

- R_7 represents a phenyl group that is optionally substituted on its aromatic ring with 1, 2, 3, or 4 Y substituents, wherein each Y substituent may be the same or

different, and is independently chosen from branched or linear C_{1-3} alkyl, branched or linear C_{1-3} alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

- R_7 represents a branched or linear C_{1-8} alkyl, a C_{3-10} cycloalkyl, a C_{5-10} bicyclo alkyl, a naphthyl, an amino group, a C_{1-8} dialkylamino, a C_{1-8} monoalkylamino or a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains 1 or 2 nitrogen atoms, and optionally comprises a heteroatom chosen from O and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl or hydroxy group;

- R_8 represents a hydrogen atom; and

- R_9 represents a hydrogen atom.

15. (New) The compound of claim 13, wherein said compound is chosen from:

-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(exo-2-bicyclo[2.2.1]heptyl)-4,5-dihydro-1H-imidazole-4-carboxamide (diastereomer A),

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(exo-2-bicyclo[2.2.1]heptyl)-4,5-dihydro-1H-imidazole-4-carboxamide (diastereomer B),

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-imidazole-4-carboxamide,

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-cyclohexyl-4,5-dihydro-1H-imidazole-4-carboxamide,

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[(4-chlorophenyl)-sulfonyl]-4,5-dihydro-1H-imidazole-4-carboxamidine,

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[(4--fluorophenyl)-sulfonyl]-4,5-dihydro-1H-imidazole-4-carboxamidine,

- 2-(4-chlorophenyl)-N-(dimethylaminosulfonyl)-1-phenyl-4,5-dihydro-1H-imidazole-4-carboxamindine, and

- 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(dimethylaminosulfonyl)-4,5-dihydro-1H-imidazole-4-carboxamidine.

16. (New) A pharmaceutical composition comprising:

- at least one pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance; and

- a pharmaceutically effective amount of at least one compound of formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing:



(I)

wherein:

- R_1 and R_2, each independently represent a phenyl, a thienyl, or a pyridyl group, which groups are optionally substituted with 1, 2, or 3 substituents Y, wherein said Y substituents, which may be the same or different, are each independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups, or

- R_1 or R_2, or both R_1 and R_2, represent naphthyl;

- X represents a subgroup chosen from (i) and (ii),



(i)



(ii)

wherein:

- R_3 is chosen from a hydrogen atom and a branched or linear C_{1-3} alkyl group;

- R_4 is chosen from:

  - a branched or linear C_{1-8}-alkyl or C_{3-8}-cycloalkyl-C_{1-2}-alkyl, branched or linear C_{1-8} alkoxy, C_{3-8} cycloalkyl, C_{5-10} bicycloalkyl, or C_{6-10} tricycloalkyl group, which groups optionally contain one or more heteroatoms chosen from O, N, and S, and which groups are optionally substituted with a hydroxy group, 1-3 methyl groups, an ethyl group, or 1-3 fluoro atoms; or

  - a phenoxy, benzyl, phenethyl or phenylpropyl group, which groups are each optionally substituted on their phenyl ring with 1-3 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or

linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

- a pyridyl or thienyl group; and

- a group NR_5R_6, wherein:

- R_5 and R_6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a hydroxy or a trifluromethyl group or a fluoro atom; or

- R_3 and R_4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a amino, a hydroxy or a trifluoromethyl group, or a fluoro atom;

- R_7 represents a benzyl, phenyl, thienyl or pyridyl group, wherein the aromatic ring of said group is optionally substituted with 1, 2, 3 or 4 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3} alkyl, a branched or linear C_{1-3} alkoxy, a phenyl, a hydroxy, a chloro, a bromo, a fluoro, an iodo, a trifluoromethyl, a trifluoromethylthio, a trifluoromethoxy, a carboxyl, a trifluoromethylsulfonyl, a cyano, a carbamoyl, a sulfamoyl, and an acetyl group; or

- R_7 represents a branched or linear C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-10} cycloalkyl, C_{5-10} bicycloalkyl, C_{6-10} tricycloalkyl, or a branched or linear C_{5-8} cycloalkenyl; a naphthyl group, an amino group, a C_{1-8} dialkylamino group, a C_{1-8} monoalkylamino group, or a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains 1 or 2 nitrogen atoms and optionally contains a heteroatom chosen from O and S, and is optionally substituted with a branched or linear C_{1-3} alkyl, phenyl, hydroxy or trifluoromethyl group or a fluoro atom;

- R_8 represents a hydrogen atom or a methyl group; and

- R_9 represents a hydrogen atom or a methyl, ethyl, or methoxy group.

17. (New) The composition of claim 16, wherein said at least one compound of formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing, is present in an amount effective for treating at least one disease or disorder chosen from psychiatric disorders, neurological disorders, and diseases involving cannabinoid neurotransmission, or a combination of any of the foregoing.

18. (New) The composition of claim 17, wherein said at least one psychiatric disorder, neurological disorder, or disease involving cannabinoid neurotransmission is chosen from psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, juvenile obesity, drug induced obesity, addiction, impulse control disorders, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis,

traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, pain disorders, neuropathic pain disorders, septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric ulcers, diarrhea, cardiovascular disorders, atherosclerosis, liver cirrhosis, sexual disorders, and a combination of two or more of the foregoing diseases or disorders.

19. (New) A method for preparing a pharmaceutical composition comprising: mixing a pharmaceutically effective amount of at least one compound of formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing:



(I)

wherein:

- R_1 and R_2, each independently represent a phenyl, a thienyl, or a pyridyl group, which groups are optionally substituted with 1, 2, or 3 substituents Y, wherein said Y substituents, which may be the same or different, are each independently chosen from

branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups, or

- R_1 or R_2, or both R_1 and R_2, represent naphthyl;

- X represents a subgroup chosen from (i) and (ii),



(i) (ii)

wherein:

- R_3 is chosen from a hydrogen atom and a branched or linear C_{1-3} alkyl group;

- R_4 is chosen from:

- a branched or linear C_{1-8}-alkyl or C_{3-8}-cycloalkyl-C_{1-2}-alkyl, branched or linear C_{1-8} alkoxy, C_{3-8} cycloalkyl, C_{5-10} bicycloalkyl, or C_{6-10} tricycloalkyl group, which groups optionally contain one or more heteroatoms chosen from O, N, and S, and which groups are optionally substituted with a hydroxy group, 1-3 methyl groups, an ethyl group, or 1-3 fluoro atoms; or

- a phenoxy, benzyl, phenethyl or phenylpropyl group, which groups are each optionally substituted on their phenyl ring with 1-3 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

- a pyridyl or thienyl group; and

- a group NR_5R_6, wherein:

- R_5 and R_6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a hydroxy or a trifluoromethyl group or a fluoro atom; or

- R_3 and R_4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a amino, a hydroxy or a trifluoromethyl group, or a fluoro atom;

- R_7 represents a benzyl, phenyl, thienyl or pyridyl group, wherein the aromatic ring of said group is optionally substituted with 1, 2, 3 or 4 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3} alkyl, a branched or linear C_{1-3} alkoxy, a phenyl, a hydroxy, a chloro, a bromo, a fluoro, an iodo, a trifluoromethyl, a trifluoromethylthio, a trifluoromethoxy, a carboxyl, a trifluoromethylsulfonyl, a cyano, a carbamoyl, a sulfamoyl, and an acetyl group; or

- R_7 represents a branched or linear C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-10} cycloalkyl, C_{5-10} bicycloalkyl, C_{6-10} tricycloalkyl, or a branched or linear C_{5-8} cycloalkenyl; a naphthyl group, an amino group, a C_{1-8} dialkylamino group, a C_{1-8} monoalkylamino group, or a

saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains 1 or 2 nitrogen atoms and optionally contains a heteroatom chosen from O and S, and is optionally substituted with a branched or linear C_{1-3} alkyl, phenyl, hydroxy or trifluoromethyl group or a fluoro atom;

- R_8 represents a hydrogen atom or a methyl group; and
- R_9 represents a hydrogen atom or a methyl, ethyl, or methoxy group,

with at least one pharmaceutically acceptable carrier, at least one pharmaceutically acceptable auxiliary substance, or a combination thereof.

20. (New) A method for the treatment of at least one psychiatric disorder, neurological disorder, or disease involving cannabinoid neurotransmission, comprising:

administering a pharmaceutical composition to a patient in need of said treatment,

wherein the pharmaceutical composition comprises a pharmaceutically effective amount of at least one compound of formula (I), or a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a salt of any of the foregoing:



(I)

wherein:

- R_1 and R_2, each independently represent a phenyl, a thienyl, or a pyridyl group, which groups are optionally substituted with 1, 2, or 3 substituents Y, wherein said Y substituents, which may be the same or different, are each independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups, or

- R_1 or R_2, or both R_1 and R_2, represent naphthyl;

- X represents a subgroup chosen from (i) and (ii),



(i) (ii)

wherein:

- R_3 is chosen from a hydrogen atom and a branched or linear C_{1-3} alkyl group;

- R_4 is chosen from:

- a branched or linear C_{1-8}-alkyl or C_{3-8}-cycloalkyl-C_{1-2}-alkyl, branched or linear C_{1-8} alkoxy, C_{3-8} cycloalkyl, C_{5-10} bicycloalkyl, or C_{6-10} tricycloalkyl group, which groups optionally contain one or more heteroatoms chosen from O, N, and S, and which groups are optionally substituted with a hydroxy group, 1-3 methyl groups, an ethyl group, or 1-3 fluoro atoms; or

- a phenoxy, benzyl, phenethyl or phenylpropyl group, which groups are each optionally substituted on their phenyl ring with 1-3 Y substituents, wherein each Y

substituent may be the same or different, and is independently chosen from branched or linear C_{1-3}-alkyl, branched or linear C_{1-3}-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl groups; or

- a pyridyl or thienyl group; and

- a group NR_5R_6, wherein:

- R_5 and R_6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a hydroxy or a trifluoromethyl group or a fluoro atom; or

- R_3 and R_4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, which heterocyclic group contains one or two heteroatoms chosen from O, N, and S, and which group is optionally substituted with a branched or linear C_{1-3} alkyl, a phenyl, a amino, a hydroxy or a trifluoromethyl group, or a fluoro atom;

- R_7 represents a benzyl, phenyl, thienyl or pyridyl group, wherein the aromatic ring of said group is optionally substituted with 1, 2, 3 or 4 Y substituents, wherein each Y substituent may be the same or different, and is independently chosen from branched or linear C_{1-3} alkyl, a branched or linear C_{1-3} alkoxy, a phenyl, a hydroxy, a chloro, a bromo, a fluoro, an iodo, a trifluoromethyl, a trifluoromethylthio, a trifluoromethoxy, a

carboxyl, a trifluoromethylsulfonyl, a cyano, a carbamoyl, a sulfamoyl, and an acetyl group; or

- R_7 represents a branched or linear C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-10} cycloalkyl, C_{5-10} bicycloalkyl, C_{6-10} tricycloalkyl, or a branched or linear C_{5-8} cycloalkenyl; a naphthyl group, an amino group, a C_{1-8} dialkylamino group, a C_{1-8} monoalkylamino group, or a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having from 4 to 10 ring atoms, wherein said heterocyclic group contains 1 or 2 nitrogen atoms and optionally contains a heteroatom chosen from O and S, and is optionally substituted with a branched or linear C_{1-3} alkyl, phenyl, hydroxy or trifluoromethyl group or a fluoro atom;

- R_8 represents a hydrogen atom or a methyl group; and

- R_9 represents a hydrogen atom or a methyl, ethyl, or methoxy group.

21. (New) The method of claim 20, wherein said at least one psychiatric disorder, neurological disorder, or disease involving cannabinoid neurotransmission is chosen from psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, juvenile obesity, drug induced obesity, addiction, impulse control disorders, appetence, drug dependence, neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, pain disorders,

neuropathic pain disorders, septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric ulcers, diarrhea, cardiovascular disorders, atherosclerosis, liver cirrhosis, sexual disorders, and a combination of two or more of the foregoing diseases or disorders.

22. (New) The method of claim 21, wherein said at least one disorder or disease is chosen from eating disorders.

23. (New) The method of claim 22, wherein said at least one disorder or disease is chosen from obesity, juvenile obesity, and drug induced obesity.

24. (New) The pharmaceutical composition of claim 16, wherein said pharmaceutical composition further comprises at least one lipase inhibitor.

25. (New) The pharmaceutical composition of claim 24, wherein said at least one lipase inhibitor is chosen from orlistat and lipstatin.